Carolina Marchena is a Senior Clinical Trials Assistant at Proxima Clinical Research, Inc., a contract research organization that serves the emerging drug and medical device industries. Carolina has 2 years of clinical research experience and 8 years of experience in the health professions education. Prior to joining the Proxima team, Carolina was a Sr. Clinical Trials Assistant with FHI 360/Infectious Disease Clinical Research Consortium (IDCRC), supporting NIH Sponsored studies. In her tenure with FHI 360, she also supported Sexually Transmitted Disease and MPOX  Expert Working Groups in the evaluation of proposals for IDCRC funding. Carolina graduated with a Bachelor’s Degree from the University of Central Florida. Carolina is deeply passionate about advancing clinical research and driven to deliver exceptional quality services while fostering a collaborative team culture.

University of Central Arkansas: Education, B.A.

Proxima Clinical Research, Inc., Houston, Texas
Sr. Clinical Trials Assistant ‍

FHI 360, Durham, North Carolina
Sr. Clinical Trials Assistant

University of Central Florida, College of Medicine, Orlando, FL
Clinical Skills and Simulation Center Assistant Director ‍

University of Central Florida, College of Medicine, Orlando, FL
Practice of Medicine Coordinator

Ms. Marchena has played an important role in the development of the following:

1. Interventional, Randomized, Open-label Study to Validate an Easy to Administer Algorithm to Define Penicillin (B-lactam) Allergy Status in STD Outpatients, Examining 284 participants across 4 sites in the US.  
2. Phase 2, Randomized, Blinded Study; to evaluate Mucosal Immune Responses Against Neisseria Gonorrhoeae following meningococcal Immunization in Healthy Young Adults, Examining 52 participants, 1 site US.
3. A Phase 1, Open-label Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults, Examining 82 participants across 4 sites in the US.  
4. Phase 1, Open Label, Randomized Study of the Safety and Immunogenicity of SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naive and Previously Vaccinated Adults, Examining 135 participants across 4 sites in the US.